AACR Cancer Progress Report 2022
On September 21, 2022, the AACR released the 12th edition of its AACR Cancer Progress Report, an annual report that chronicles how basic, translational, and clinical cancer research, and cancer-related population sciences, primarily supported by federal investments in the National Institutes of Health (NIH) and the National Cancer Institute (NCI), remain vitally important to improving health and saving lives.
Read the AACR Cancer Progress Report 2022.
MEDIA COVERAGE
Major broadcast media outlets including ABC News, NBC News, CBS News, and CNN covered the report with online stories. Each of these outlets also discussed the report on their television programs, such as ABC’s Good Morning America, NBC’s TODAY Show, CBS Mornings, and multiple programs on CNN with commentary from Chief Medical Correspondent Dr. Sanjay Gupta. The report was also covered on local news programs and radio stations across the country, in consumer publications such as People magazine, and in cancer trade publications such as HemOnc Today.
See highlights of media coverage featuring the AACR Cancer Progress Report 2022 below.
ABC News: Cancer deaths in US declined by 2% every year since 2016, report says.
Learn More
NBC News: Cancer death rates continue to fall, driven by new treatments and improved screening.
Learn More
CBS News: “More people than ever” are surviving cancer in the U.S., study shows, as research and treatment see “unprecedented progress.”
Learn More
CNN: Cancer death rates in the US are falling steadily. Here’s why.
Learn More
People: New report shows decline in cancer deaths, with more than 18 million cancer survivors in the U.S.
Learn More
TODAY Show: Cancer deaths in US fall steadily with better treatments, prevention.
Learn More
AXIOS: Cancer deaths fall with new treatments and better screening.
Learn More
Health: More people are surviving cancer than ever before, new report shows.
Learn More
HemOnc Today: AACR report: Cancer deaths decline 2.3% amid treatment advances, but disparities persist.
Learn More